Can Guardant Health (GH) Justify Its Valuation As COSMOS MEL01 Data Strengthens Reveal?
Alpha Vantage · Simply Wall Street · · AI-summarised by FinFlash
Guardant Health (GH) is gaining attention after new COSMOS-MEL01 data showcased the high specificity and sensitivity of its Guardant Reveal blood test for detecting molecular residual disease and melanoma recurrence. Despite recent share price gains, the company's valuation is seen as 18% undervalued by some analysts, with a fair value of around Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.Understand the context